News & Events

BEAM Alliance
Members
Events

Latest news from BEAM Alliance

3 March 2026 - BEAM ALLIANCE

BEAM is turning 10!

What a journey since the association was founded in 2016! Since then, awareness of the looming AMR problem has grown,…

11 December 2025 - BEAM ALLIANCE

EU Reaches Landmark Agreement on Pharmaceutical Legislation Revision

After a long night of negotiations, EU co-legislators have reached a long-awaited political agreement on the revision of the Union’s…

20 October 2025 - BEAM ALLIANCE

Defining Eligibility for ‘Priority Antimicrobials’: A Critical Step for Effective PULL Incentives

The General Pharmaceutical Legislation (GPL) should provide broad guidelines for eligibility, leaving the EMA to refine the details. The GPL…

20 October 2025 - BEAM ALLIANCE

Transferable Priority Review Vouchers (TPRVs): Lessons from the US, Implications for EU

If a choice must be made, TEEV offer a clearer, more reliable incentive for SMEs, making them a more appealing…

20 October 2025 - BEAM ALLIANCE

The Future of the TEE Voucher in EU Pharmaceutical Legislation

The TEE Voucher is widely supported by SMEs, industry, and investors. Though not perfect, its predictability makes it attractive to…

20 October 2025 - BEAM ALLIANCE

How Can a Subscription Model Help Incentivizing Antimicrobial Innovation in the EU?

An EU-funded revenue guarantee (ensuring predictability and reducing reliance on voluntary participation) could be highly effective, provided the incentives are…

No results

1 / 10

Latest news of BEAM Members

23 March 2026 - ANTABIO

Antabio and GARDP join forces to identify potential next-generation antibiotics

Drug-resistant infections are rising at an alarming pace, leaving patients worldwide with too few effective treatment options,” said Marc Lemonnier,…

23 March 2026 - Basilea Pharmaceutica International

Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

BAL2420 offers a novel mode of action to address serious Gram‑negative bacterial infections, which remain of particular concern because of…

16 March 2026 - AUROBAC THERAPEUTICS

AUROBAC Successfully Completes Phase 1 Clinical Trial of ATX101 and Prepares for Phase 2

ATX101 is a potential first-in-class treatment, addressing shock, organ failure and mortality in sepsis.

16 March 2026 - BioVersys

BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start

BV100 has Qualified Infectious Disease Product (QIDP) Designation from the U.S. FDA, making BV100 eligible for priority FDA review, Fast Track designation,…

12 March 2026 - BioVersys

BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis

The compound represents a novel concept to overcome resistance and potentiate the activity of an existing antibiotic, ethionamide (Eto) or…

10 March 2026 - Centauri Therapeutics

Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections

The recognition of the potential value of our technology further underpins our belief in its potential to transform treatment paradigms…

No results

1 / 71

Events

25 June 2026

Therapeutics and Antimicrobial Resistance (AMR)

The meeting aims to strengthen cross-disciplinary connections, highlight opportunities for impact, and catalyse new initiatives in therapeutics research, outreach and…

17 April 2026

ESCMID Global 2026

ESCMID Global is the world’s premier meeting in the fields of Clinical Microbiology and Infectious Diseases.

26 March 2026

REVIVE Webinar: Journal Club: Key findings from recent publications in antimicrobial R&D

In this webinar, individuals who have co-authored publications that have had particular impact in the field of antimicrobial R&D will…

13 March 2026

REVIVE Webinar: Current developments in Clostridioides difficile prevention, therapy and R&D

REVIVE webinar being done in collaboration with the Peggy Lillis Foundation

3 March 2026

10th AMR Conference

Save the date! The 10th AMR Conference will be organized as a face-to-face event on 3-4 March 2026, in Basel.…

19 February 2026

REVIVE Webinar: Innovating for Impact: Tackling Chronic Lung Infections in Cystic Fibrosis through New Antimicrobials

REVIVE webinar in collaboration with CF AMR Syndicate.

No results

1 / 30

Legal notice | Photo credits

Connect with us

contact@beam-alliance.eu
29 Avenue Tony Garnier 69007 Lyon - France